Patents by Inventor Malcolm Norman Palfreyman

Malcolm Norman Palfreyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds as PDE IV and TNF inhibitors
    Patent number: 8129537
    Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: March 6, 2012
    Assignees: Rhone-Poulenc Rorer Limited, Aventis Pharma Limited
    Inventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
  • Compounds as PDE IV and TNF Inhibitors
    Publication number: 20100240677
    Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
    Type: Application
    Filed: January 26, 2010
    Publication date: September 23, 2010
    Applicant: AVENTIS PHARMA LIMITED
    Inventors: Garry FENTON, Tahir Nadeem MAJID, Malcolm Norman PALFREYMAN
  • Compounds as PDE IV and TNF inhibitors
    Patent number: 7652144
    Abstract: A compound of formula XIX wherein R1, R2, Z1, Z2, Q1, Q2 and Q3 as defined in the specification.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: January 26, 2010
    Assignee: Aventis Pharma Limited
    Inventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
  • Compounds as PDE IV and TNF Inhibitors
    Publication number: 20080132706
    Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
    Type: Application
    Filed: June 18, 2007
    Publication date: June 5, 2008
    Applicant: AVENTIS PHARMA LIMITED
    Inventors: Garry FENTON, Tahir Nadeem MAJID, Malcolm Norman PALFREYMAN
  • Compounds as PDE IV and TNF-inhibitors
    Patent number: 7045660
    Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: May 16, 2006
    Assignee: Aventis Pharma Limited
    Inventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
  • Compounds as PDE IV and TNF-inhibitors
    Publication number: 20040171618
    Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).
    Type: Application
    Filed: March 3, 2004
    Publication date: September 2, 2004
    Applicant: AVENTIS PHARMA LIMITED
    Inventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
  • Compounds as PDE IV and TNF inhibitors
    Patent number: 6472412
    Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
    Type: Grant
    Filed: January 26, 1996
    Date of Patent: October 29, 2002
    Assignee: Aventis Pharma Limited
    Inventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
  • Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
    Patent number: 6255326
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: July 3, 2001
    Assignee: Aventis Pharma Limited
    Inventors: Michael John Ashton, David Charles Cook, Garry Fenton, Susan Jacqueline Hills, Ian Michael McFarlane, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Nigel Vicker
  • Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
    Patent number: 6096768
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: August 1, 2000
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Michael John Ashton, David Charles Cook, Garry Fenton, Susan Jacqueline Hills, Ian Michael McFarlane, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Nigel Vicker
  • Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
    Patent number: 5935978
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: July 28, 1993
    Date of Patent: August 10, 1999
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Garry Fenton, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Michael John Ashton, David Charles Cook, Susan Jacqueline Hills, Ian Michael McFarlane, Nigel Vicker
  • Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- o r
    Patent number: 5840724
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: November 24, 1998
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Garry Fenton, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Keith Alfred James Stuttle, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher
  • Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
    Patent number: 5698711
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 16, 1997
    Assignee: Rhone-Poulenc Rorer Limited
    Inventor: Malcolm Norman Palfreyman
  • Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
    Patent number: 5679696
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 21, 1997
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Garry Fenton, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Keith Alfred James Stuttle, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher